核苷类药物治疗肝硬化失代偿期疗效观察

Nucleoside drugs decompensated cirrhosis clinical observation period

目的评价核苷(酸)类抗病毒药物对失代偿期肝硬化患者的临床疗效。方法 98例患者随机分为治疗组和对照组,平均随访72周,随访结束时分析患者临床症状、体征、肝功能变化、凝血酶原时间活动度、HBV-DNA定量、HBeAg阴转、HBeAg/HBeAb转换情况。结果治疗组血清谷草转氨酶、谷丙转氨酶、球蛋白、总胆红素均较治疗前下降,血清白蛋白及胆碱酯酶较治疗前升高,差异有统计学意义。91.6%病例血清HBV-DNA由阳性转至检测水平以下(HBV-DNA<103 copies/ml)。结论核苷类抗病毒药物可以改善乙型肝炎肝硬化特别是失代偿期肝硬化患者的肝脏功能指标,改善患者的预后。

Objective To evaluate nucleoside analogues coming antiviral drugs to decompensated cirrhosis period of clinical effect. Methods 98 cases were randomly divided into the treatment group and control group, the average follow - up 72 weeks, in the end of follow- up analysis the clinical symptoms, signs, liver function change, prothrombin time mobility （ PTA）, HBV - DNA ration, HBeAg Yin turn, HBeAb conversion HBeAg. Results The treatment group serum aspertate aminotransferase）, cereal third transaminase, globulin, total bilirubin were relatively before treatment, serum albumin and drop cho- linesterase is elevatory, differences before treatment with a statistical significance. 91.6% cases by positive serum HBV - DNA levels below transferred to detection （ HBV - DNA 〈 103 copies/ml）. Conclusion Nucleoside antiviral drugs to improve hepati- tis b liver cirrhosis especially decompensated cirrhosis of the liver function （ index, improve the prognosis of patients.